Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharvaris NV PHVS

Healthcare Biotechnology
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Recent & Breaking News (NDAQ:PHVS)

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

GlobeNewswire November 13, 2024

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

GlobeNewswire November 12, 2024

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

GlobeNewswire October 24, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

GlobeNewswire October 16, 2024

Pharvaris to Host Virtual Investor Event on October 23, 2024

GlobeNewswire October 15, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

GlobeNewswire October 3, 2024

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

GlobeNewswire September 5, 2024

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

GlobeNewswire September 5, 2024

Pharvaris Presents Data at the Bradykinin Symposium 2024

GlobeNewswire September 5, 2024

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

GlobeNewswire August 28, 2024

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

Pharvaris Announces Annual Meeting of Shareholders

GlobeNewswire June 11, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

GlobeNewswire June 4, 2024

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

GlobeNewswire May 13, 2024

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 8, 2024

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire April 10, 2024

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

GlobeNewswire April 10, 2024

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

GlobeNewswire April 4, 2024

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

GlobeNewswire March 18, 2024

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

GlobeNewswire March 6, 2024